Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
After years of failure, the Maryland company aims to attract the vaccine-hesitant with an alternative to mRNA shots. But will it find a market?
Showing 81 - 100 of 110
-
-
Why Cheap, Older Drugs That Might Treat Covid Never Get Out of the Lab
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
By Arthur Allen -
Why Black and Hispanic Seniors Are Left With a Less Powerful Flu Vaccine
Federal health officials haven’t taken a clear position on whether a high-dose influenza vaccine — on the market since 2010 — is the best choice for people 65 and older. Many in that group already opt for the costlier enhanced shot. Those who get the standard vaccine are disproportionately members of ethnic and racial minorities.
By Arthur Allen -
Pfizer CEO Pushes Yearly Shots for Covid. Not So Fast, Experts Say.
A corporate CEO’s call for a fourth mRNA shot struck those closely watching the pandemic as self-serving. It creates public pressure for a fourth dose of vaccine before government experts have time to assess the evidence and settle on the best course forward.
By Arthur Allen -
Inside the Tactical Tug of War Over the Controversial Alzheimer’s Drug
An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work.
By Arthur Allen -
Perspective
How LA, Calling the Shots on School Vaccine Mandates, Can Lead the Way on Covid Rules
In the middle of a measles outbreak in 1977, the Los Angeles school system required students to be inoculated or stay out of class. Other school systems followed the practice. Will it work again now that the county is insisting that teens have their shots against covid?
By Arthur Allen -
Stranded by the Pandemic, He Had Only Travel Insurance. It Left Him With a $38,000 Bill.
Although it’s possible to buy travel insurance that provides some health coverage, the devil is in the fine print. Obama-era laws that prevent refusal of payment for preexisting conditions don’t apply to travel insurance.
By Arthur Allen -
Covid Immunity Through Infection or Vaccination: Are They Equal?
As scientists argue whether a previous bout of covid offers the same amount of protection as vaccinations, people turn to the courts to decide.
By Arthur Allen -
How Fauci and the NIH Got Ahead of the FDA and CDC in Backing Boosters
With real-time data streaming in from highly specialized researchers in the U.S. and abroad, NIH scientists became convinced that boosting the covid-19 vaccine was needed to save lives, prompting the president to announce a plan with a Sept. 20 start date. Scientists at the regulatory agencies weren’t yet convinced. A meeting Friday will determine what happens next. Here’s the story from behind the scenes.
By Sarah Jane Tribble and Arthur Allen -
Federal Vaccine Program Hasn’t Helped Those Whose Lives Were Altered by Covid Shot
A national vaccine court has paid out billions to families who could prove their kids were injured by vaccines. But there’s only a skeletal program for the rare victims of covid vaccination, raising concerns as the pressure for mandated shots grows.
By Arthur Allen -
Not All Experts Are Ready to Vaccinate Kids Against Covid
Rare reports of minor heart damage have convinced some scientists that further study is needed before racing to extend covid shots to more children.
By Arthur Allen -
Analysis: Mounting Pressure on China About Covid ‘Lab Leak’ Could Backfire
Where the coronavirus originated remains a mystery and the Chinese are bucking demands to let investigators see more.
By Arthur Allen -
To the Bat Cave: In Search of Covid’s Origins, Scientists Reignite Polarizing Debate on Wuhan ‘Lab Leak’
Leading virologists, including Dr. Anthony Fauci, are demanding a deeper probe into China’s Wuhan Institute of Virology as they try to identify the source of the deadly coronavirus.
By Arthur Allen -
This Small Canadian Drugmaker Wants to Make J&J Vaccines for Poor Nations. It Needs More Than a Patent Waiver.
All agree that covid vaccines are urgently needed to stop the pandemic, but simply waiving patents fails to provide technological know-how and address supply chain challenges.
By Sarah Jane Tribble and Arthur Allen -
You Don’t Have to Suffer to Benefit From Covid Vaccination — But Some Prefer It
In the times of smallpox, vaccination was accompanied by blood, sweat, fire and brimstone. Nowadays, a slight fever may make you feel as if you’ve earned the reward of immunity from covid. But you’re protected even without a nasty reaction to the vaccine.
By Arthur Allen -
The Case for Donating US Covid Vaccines Overseas
For now, there’s not enough vaccine for the U.S., but that could change within a few months. Vaccinating other nations will be key to stopping the pandemic – and keeping it away from our shores.
By Arthur Allen -
‘Explained by KHN’: Consumer Concerns About the Covid Vaccines
Our newsroom has some of the best and smartest health care and health policy reporters in the business. We’ve created a new video series — “Explained by KHN” — in which our correspondents and editors answer common health care and policy questions. In this edition we cover consumer concerns over the covid-19 vaccines.
-
To Extract More Doses per Vial, Vaccinators Put Squeeze on FDA to Relax Vaccine Handling Advice
Although vaccine supply is ramping up, the supply gap puts pressure on vaccinating teams to extract every drop they can. Some are asking the FDA to waive guidance against extracting vaccine from two vials with the same needle. It’s worth a shot.
By Arthur Allen -
After Billions of Dollars and Dozens of Wartime Declarations, Why Are Vaccines Still in Short Supply?
The Trump and Biden administrations both imposed wartime production requirements. But industry experts say the vast quantities of raw materials and specialty equipment needed for billions of newfangled vaccines have required herculean logistical efforts.
By Rachana Pradhan and Arthur Allen -
When Your Chance for a Covid Shot Comes, Don’t Worry About the Numbers
The Johnson & Johnson vaccine that the FDA cleared Saturday was 66% effective overall in preventing moderate to severe covid, while the Pfizer and Moderna vaccines were more than 90% effective. But the numbers aren’t exactly comparable. And all three shots prevent hospitalization and death.
By Arthur Allen and Liz Szabo
Sign Up For Our Newsletter
Stay informed by signing up for the Morning Briefing and other emails: